Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
NYSE:SYK

Stryker (SYK) Stock Price, News & Analysis

$363.76
+2.40 (+0.66%)
(As of 11:45 AM ET)

About Stryker Stock (NYSE:SYK)

Key Stats

Today's Range
$362.62
$365.70
50-Day Range
$315.94
$371.97
52-Week Range
$249.98
$374.63
Volume
249,423 shs
Average Volume
1.28 million shs
Market Capitalization
$138.62 billion
P/E Ratio
41.53
Dividend Yield
0.88%
Price Target
$378.58
Consensus Rating
Moderate Buy

Company Overview

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Stryker Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 92nd Percentile

Stryker scored higher than 92% of companies evaluated by MarketBeat, and ranked 89th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Stryker has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 15 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Stryker has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Stryker's stock forecast and price target.
  • Earnings Growth

    Earnings for Stryker are expected to grow by 12.08% in the coming year, from $12.00 to $13.45 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Stryker is 41.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.51.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Stryker is 41.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 147.31.

  • Price to Earnings Growth Ratio

    Stryker has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Stryker has a P/B Ratio of 7.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Stryker's valuation and earnings.
  • Percentage of Shares Shorted

    1.24% of the float of Stryker has been sold short.
  • Short Interest Ratio / Days to Cover

    Stryker has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Stryker has recently increased by 18.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Stryker has a dividend yield of 0.86%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Stryker does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Stryker is 36.53%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Stryker will have a dividend payout ratio of 23.79% next year. This indicates that Stryker will be able to sustain or increase its dividend.

  • Read more about Stryker's dividend.
  • Percentage of Shares Shorted

    1.24% of the float of Stryker has been sold short.
  • Short Interest Ratio / Days to Cover

    Stryker has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Stryker has recently increased by 18.67%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Stryker has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for Stryker this week, compared to 12 articles on an average week.
  • Search Interest

    Only 8 people have searched for SYK on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Stryker to their MarketBeat watchlist in the last 30 days. This is a decrease of -69% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Stryker insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,811,372.00 in company stock.

  • Percentage Held by Insiders

    Only 5.90% of the stock of Stryker is held by insiders.

  • Percentage Held by Institutions

    77.09% of the stock of Stryker is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Stryker's insider trading history.

SYK Stock News Headlines

Stryker Co. (NYSE:SYK) VP Sells $2,696,202.06 in Stock
Central Bank Abandons USD
Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.
Tula, Russia - october 19, 2021: Boston Scientific displayed modern laptop on red background — Stock Editorial Photography
Boston Scientific: Why This MedTech Giant Isn’t Slowing Down (SYK)
Boston Scientific Co (NYSE: BSX) is a global medical device manufacturer that’s seeing a strong influx of investors as shares grind to new all-time highs.
Medtronic stock price
Medtronic Stock: Growth On Rise of the Cardiovascular Machines (SYK)
Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases
M Kathryn Fink Sells 2,121 Shares of Stryker Co. (NYSE:SYK) Stock
M Kathryn Fink Sells 7,347 Shares of Stryker Co. (NYSE:SYK) Stock
Stryker executive sells over $3.4 million in company stock
See More Headlines

SYK Stock Analysis - Frequently Asked Questions

Stryker's stock was trading at $299.46 at the beginning of 2024. Since then, SYK stock has increased by 21.6% and is now trading at $364.17.
View the best growth stocks for 2024 here
.

Stryker Co. (NYSE:SYK) posted its quarterly earnings data on Tuesday, July, 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.79 by $0.02. Stryker's revenue for the quarter was up 8.5% compared to the same quarter last year.
Read the conference call transcript
.

Stryker subsidiaries include these companies: Vocera Communications, Vocera, Gauss Surgical, OrthoSensor, Wright Medical Group, Cardan Robotics, Mobius Imaging, and more.

Stryker's top institutional shareholders include Bank of New York Mellon Corp (1.49%), First Western Trust Bank (0.92%), Legal & General Group Plc (0.75%) and Clearbridge Investments LLC (0.61%). Insiders that own company stock include Ronda E Stryker, Kevin Lobo, James Andrew Pierce, Allan C Golston, M Kathryn Fink, Viju Menon, Robert S Fletcher, Srikant M Datar, William E Berry Jr and Glenn S Boehnlein.
View institutional ownership trends
.

Shares of SYK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stryker investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), Home Depot (HD), Medtronic (MDT), Visa (V), AbbVie (ABBV) and Cisco Systems (CSCO).

Company Calendar

Ex-Dividend for 7/31 Dividend
6/28/2024
Last Earnings
7/30/2024
Dividend Payable
7/31/2024
Today
9/19/2024
Ex-Dividend for 10/31 Dividend
9/30/2024
Dividend Payable
10/31/2024
Next Earnings (Estimated)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
86366710
Employees
52,000
Year Founded
1941

Price Target and Rating

Average Stock Price Target
$378.58
High Stock Price Target
$406.00
Low Stock Price Target
$345.00
Potential Upside/Downside
+4.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
19 Analysts

Profitability

Net Income
$3.17 billion
Pretax Margin
18.78%

Debt

Sales & Book Value

Annual Sales
$20.50 billion
Cash Flow
$13.09 per share
Book Value
$48.94 per share

Miscellaneous

Free Float
358,474,000
Market Cap
$138.33 billion
Optionable
Optionable
Beta
0.91

Social Links

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 4, 2024. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Stryker Co.:

  • Stryker Co. has consistently shown strong financial performance with a solid return on equity of 22.89%, indicating efficient use of shareholder funds.
  • The company has a diverse product portfolio across its MedSurg, Neurotechnology, and Orthopaedics and Spine segments, reducing dependency on any single market.
  • Recent insider selling activities, including the CFO selling shares at $333.00, could indicate confidence in the company's future performance.
  • Stryker Co. announced a quarterly dividend of $0.80 per share, reflecting a stable dividend payout ratio of 36.53% and a yield of 0.89% for investors seeking income.
  • Analysts have given Stryker Co. an average rating of "Moderate Buy" with a target price of $373.84, suggesting potential upside for investors based on market expectations.

Stryker
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Stryker Co. for these reasons:

  • The recent insider selling activities, with insiders selling a significant number of shares, may raise concerns about the company's future growth prospects.
  • Stryker Co.'s stock price has been relatively stagnant, trading down 0.2% recently, which could indicate limited short-term price appreciation potential.
  • The company's P/E ratio of 41.14 and price-to-earnings-growth ratio of 2.78 suggest that the stock may be currently overvalued compared to its growth prospects.
  • While the company has a strong market capitalization of $137.35 billion, the beta of 0.89 indicates that the stock may be less volatile than the market average, potentially limiting potential returns for risk-seeking investors.
  • Despite positive earnings results, Stryker Co. faces competition in the medical technology sector, which could impact its market share and profitability in the long term.

This page (NYSE:SYK) was last updated on 9/19/2024 by MarketBeat.com Staff
From Our Partners